Page last updated: 2024-10-31

midazolam and Invasiveness, Neoplasm

midazolam has been researched along with Invasiveness, Neoplasm in 1 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research Excerpts

ExcerptRelevanceReference
"Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing."2.73A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yong, WP1
Wang, LZ1
Tham, LS1
Wong, CI1
Lee, SC1
Soo, R1
Sukri, N1
Lee, HS1
Goh, BC1

Trials

1 trial available for midazolam and Invasiveness, Neoplasm

ArticleYear
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R

2008